CMV esophagitis - Revision history

Ostermayer: Marked this version for translation

2026-01-07T12:26:15Z

Marked this version for translation

← Older revision		Revision as of 12:26, 7 January 2026
Line 2:		Line 2:
	<translate>		<translate>

	==Background==		==Background== <!--T:1-->

			<!--T:2-->
	*[[Special:MyLanguage/Cytomegalovirus\|Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[Special:MyLanguage/AIDS\|AIDS]].		*[[Special:MyLanguage/Cytomegalovirus\|Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[Special:MyLanguage/AIDS\|AIDS]].
	*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.		*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
Line 9:		Line 10:


	==Clinical Features==		==Clinical Features== <!--T:3-->

			<!--T:4-->
	*[[Special:MyLanguage/Odynophagia\|Odynophagia]]		*[[Special:MyLanguage/Odynophagia\|Odynophagia]]
	*[[Special:MyLanguage/Dysphagia\|Dysphagia]]		*[[Special:MyLanguage/Dysphagia\|Dysphagia]]
Line 18:		Line 20:


	==Differential Diagnosis==		==Differential Diagnosis== <!--T:5-->

	</translate>		</translate>
Line 29:		Line 31:


	==Evaluation==		==Evaluation== <!--T:6-->


	==Management==		==Management== <!--T:7-->

			<!--T:8-->
	**[[Special:MyLanguage/Ganciclovir\|Ganciclovir]]: 5mg/kg/dose IV q12h		**[[Special:MyLanguage/Ganciclovir\|Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[Special:MyLanguage/Foscarnet\|Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h		**[[Special:MyLanguage/Foscarnet\|Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
Line 42:		Line 45:


	==Disposition==		==Disposition== <!--T:9-->


	==See Also==		==See Also== <!--T:10-->

			<!--T:11-->
	*[[Special:MyLanguage/Cytomegalovirus (CMV) infection\|Cytomegalovirus (CMV) infection]]		*[[Special:MyLanguage/Cytomegalovirus (CMV) infection\|Cytomegalovirus (CMV) infection]]


	==External Links==		==External Links== <!--T:12-->


	==References==		==References== <!--T:13-->

			<!--T:14-->
	<references/>		<references/>

			<!--T:15-->
	[[Category:ID]] [[Category:GI]]		[[Category:ID]] [[Category:GI]]
	</translate>		</translate>

Ostermayer: Prepared the page for translation

2026-01-04T21:55:02Z

Prepared the page for translation

← Older revision		Revision as of 21:55, 4 January 2026
Line 1:		Line 1:
			<languages/>
			<translate>

	==Background==		==Background==
	*[[Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[AIDS]].
			*[[Special:MyLanguage/Cytomegalovirus\|Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[Special:MyLanguage/AIDS\|AIDS]].
	*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.		*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
	*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available		*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available


	==Clinical Features==		==Clinical Features==
	*[[Odynophagia]]
	*[[Dysphagia]]		*[[Special:MyLanguage/Odynophagia\|Odynophagia]]
	*[[Fever]]		*[[Special:MyLanguage/Dysphagia\|Dysphagia]]
	*[[Nausea]]		*[[Special:MyLanguage/Fever\|Fever]]
	*[[chest pain\|Substernal]] burning pain		*[[Special:MyLanguage/Nausea\|Nausea]]
			*[[Special:MyLanguage/chest pain\|Substernal]] burning pain


	==Differential Diagnosis==		==Differential Diagnosis==

			</translate>
	{{Esophagitis types}}		{{Esophagitis types}}
			<translate>

			</translate>
	{{CMV types}}		{{CMV types}}
			<translate>


	==Evaluation==		==Evaluation==


	==Management==		==Management==
	**[[Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h		**[[Special:MyLanguage/Ganciclovir\|Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[Valganciclovir]]: 900mg PO twice daily		**[[Special:MyLanguage/Foscarnet\|Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
	***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications		**[[Special:MyLanguage/Valganciclovir\|Valganciclovir]]: 900mg PO twice daily
			***May be used for induction therapy, in place of intravenous [[Special:MyLanguage/ganciclovir\|ganciclovir]], in patients who can tolerate and absorb oral medications
	**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks		**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks
	**Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.		**Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.


	==Disposition==		==Disposition==


	==See Also==		==See Also==
	*[[Cytomegalovirus (CMV) infection]]
			*[[Special:MyLanguage/Cytomegalovirus (CMV) infection\|Cytomegalovirus (CMV) infection]]


	==External Links==		==External Links==


	==References==		==References==

	<references/>		<references/>

	[[Category:ID]] [[Category:GI]]		[[Category:ID]] [[Category:GI]]
			</translate>

ClaireLewis at 20:06, 29 September 2019

2019-09-29T20:06:35Z

← Older revision		Revision as of 20:06, 29 September 2019
Line 1:		Line 1:
	==Background==		==Background==
	*Cytomegalovirus (CMV) gastrointestinal disease is an uncommon but serious complication of [[AIDS]].		*[[Cytomegalovirus]] (CMV) gastrointestinal disease is an uncommon but serious complication of [[AIDS]].
	*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.		*The diagnosis of CMV gastrointestinal disease should be suspected in patients with CD4 cell counts <50 cells/microL who present with symptoms of esophagitis, gastritis, enteritis, or colitis.
	*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available		*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available
Line 9:		Line 9:
	*[[Fever]]		*[[Fever]]
	*[[Nausea]]		*[[Nausea]]
	*Substernal burning pain		*[[chest pain\|Substernal]] burning pain

	==Differential Diagnosis==		==Differential Diagnosis==
Line 27:		Line 27:

	==Disposition==		==Disposition==
	~~===Antivirals===~~
	~~{{CMV esophagitis treatment}}~~

	==See Also==		==See Also==

ClaireLewis: /* Management */

2017-02-26T00:06:05Z

Management

← Older revision		Revision as of 00:06, 26 February 2017
Line 19:		Line 19:

	==Management==		==Management==
	*{{Induction therapy}}:
	**[[Ganciclovir]]: 5mg/kg/dose IV q12h		**[[Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h		**[[Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
Line 25:		Line 24:
	***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications		***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications
	**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks		**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks
			**Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.
	*{{Management Therapy}}:
	**Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.

	==Disposition==		==Disposition==

ClaireLewis at 00:02, 26 February 2017

2017-02-26T00:02:34Z

← Older revision		Revision as of 00:02, 26 February 2017
Line 8:		Line 8:
	*[[Dysphagia]]		*[[Dysphagia]]
	*[[Fever]]		*[[Fever]]
	*[[~~Naseau~~]]		*[[Nausea]]
	*Substernal burning pain		*Substernal burning pain

Line 21:		Line 21:
	*{{Induction therapy}}:		*{{Induction therapy}}:
	**[[Ganciclovir]]: 5mg/kg/dose IV q12h		**[[Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[~~foscarnet~~]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h		**[[Foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
	**[[Valganciclovir]]: 900mg PO twice daily		**[[Valganciclovir]]: 900mg PO twice daily
	***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications		***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications

Neil.m.young: Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-07-22T03:40:42Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Older revision		Revision as of 03:40, 22 July 2016
Line 16:		Line 16:
	{{CMV types}}		{{CMV types}}

	==~~Diagnosis~~==		==Evaluation==

	==Management==		==Management==

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-19T19:41:28Z

Text replacement - "5 mg" to "5mg"

← Older revision		Revision as of 19:41, 19 July 2016
Line 20:		Line 20:
	==Management==		==Management==
	*{{Induction therapy}}:		*{{Induction therapy}}:
	**[[Ganciclovir]]: ~~5 mg~~/kg/dose IV q12h		**[[Ganciclovir]]: 5mg/kg/dose IV q12h
	**[[foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h		**[[foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
	**[[Valganciclovir]]: 900mg PO twice daily		**[[Valganciclovir]]: 900mg PO twice daily

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-19T00:46:21Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 00:46, 19 July 2016
Line 21:		Line 21:
	*{{Induction therapy}}:		*{{Induction therapy}}:
	**[[Ganciclovir]]: 5 mg/kg/dose IV q12h		**[[Ganciclovir]]: 5 mg/kg/dose IV q12h
	**[[foscarnet]]: ~~60 mg~~/kg/dose q8h or ~~90 mg~~/kg/dose q12h		**[[foscarnet]]: 60mg/kg/dose q8h or 90mg/kg/dose q12h
	**[[Valganciclovir]]: ~~900 mg~~ PO twice daily		**[[Valganciclovir]]: 900mg PO twice daily
	***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications		***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications
	**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks		**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks

Rossdonaldson1: Text replacement - "==Clinical Presentation==" to "==Clinical Features=="

2016-07-12T07:36:36Z

Text replacement - "==Clinical Presentation==" to "==Clinical Features=="

← Older revision		Revision as of 07:36, 12 July 2016
Line 4:		Line 4:
	*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available		*The incidence of CMV gastrointestinal disease has decreased substantially since antiretroviral therapy (ART) became available

	==Clinical ~~Presentation~~==		==Clinical Features==
	*[[Odynophagia]]		*[[Odynophagia]]
	*[[Dysphagia]]		*[[Dysphagia]]

Bobzmac at 00:51, 5 August 2015

2015-08-05T00:51:24Z

← Older revision		Revision as of 00:51, 5 August 2015
Line 19:		Line 19:

	==Management==		==Management==
	*Induction therapy		*{{Induction therapy}}:
	**[[Ganciclovir]]: 5 mg/kg/dose IV q12h		**[[Ganciclovir]]: 5 mg/kg/dose IV q12h
	**[[foscarnet]]: 60 mg/kg/dose q8h or 90 mg/kg/dose q12h		**[[foscarnet]]: 60 mg/kg/dose q8h or 90 mg/kg/dose q12h
Line 25:		Line 25:
	***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications		***May be used for induction therapy, in place of intravenous [[ganciclovir]], in patients who can tolerate and absorb oral medications
	**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks		**The recommended duration of therapy for CMV gastrointestinal disease in patients with AIDS is 3-6 weeks

			*{{Management Therapy}}:
			**Chronic maintenance therapy is not recommended for CMV gastrointestinal disease unless there is concurrent retinitis or recurrent gastrointestinal disease after induction therapy has been discontinued.

	==Disposition==		==Disposition==